DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The company’s shares closed last Friday at $77.84.

DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance for revenue previously issued on February 13. See ...

Dexcom forecasts total annual revenue of $4.6bn for 2025, up from the $4bn generated in 2024. Image credit: Shutterstock/MichaelVi. Dexcom is still expected to hit ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...